c-Myc

10058-F4 is a c-Myc inhibitor that prevents c-Myc/Max dimerization.

KJ Pyr 9 is a novel small-molecule inhibitor of MYC, KJ-Pyr-9, from a Krhnke pyridine library.

ML327 is a blocker of MYC. ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition.

10074-G5 is a c-Myc inhibitor by inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity with IC50 value of 146 μM. 10074-G5 binds to and distorts the bHLH-ZIP domain of c-Myc, thereby inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity. 10074-G5 is capable of binding and sequestering the intrinsically disordered amyloid-β (Aβ) peptide in its monomeric, soluble state. Our analysis reveals that this compound interacts with Aβ and inhibits both the primary and secondary nucleation pathways in its aggregation process.

sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer with an IC50 of 1.8 μM.

IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity.

Mycro 3 is a potent and selective c-Myc inhibitor in whole cell assays.

EN4 is a covalent ligand that targets cysteine 171 (C171) of MYC. EN4 is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.

MYCi361 (NUCC-0196361) is a MYC inhibitor with the Kd of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy.

MYCi975 (NUCC-0200975) is an orally active MYC inhibitor, which disrupts MYC/MAX interaction, promotes MYC T58 phosphorylation and MYC degradation, and impairs MYC driven gene expression.

MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor.

c-Myc Peptide (TFA) is a synthetic peptide corresponding to the C-terminal amino acids (410-419) of human c-myc protein, and participates in regulation of growth-related gene transcription.